Abstract 2436
Background
RNA sequencing (RNA-Seq) assay has been widely used for transcript level gene quantification and fusion detection for research use in fresh frozen samples. Clinical use of RNA is complicated by the common use of formalin-fixed paraffin-embedded (FFPE) tissue storage, which can cause low yield and RNA degradation. We evaluate the feasibility, quality, and analytical performance of RNA-Seq on clinical FFPE tumor samples for gene fusion detection.
Methods
Total RNA was extracted from FFPE tumor samples and/or adjacent normal samples. Ribosomal RNA depletion, cDNA synthesis, and library preparation were used to prepare next-generation sequencing (NGS) libraries that were sequenced on Illumina HiSeq X instrument. Sequencing data were analyzed and annotated with an in-house developed pipeline. A set of experimental and data quality control parameters were set up.
Results
The assay identified all the positive fusions from RNA reference material with 15 NTRK fusions spiked-in and ALK, RET, NTRK1 and FGFR3 fusions from 5 positive cell lines. The assay Limit of Detection was tested by diluting RNA from ALK fusion positive cell H2228C to fusion-negative cell line. Gene fusions were generally detectable down to 10% dilutions for all fusion types and as little as 5% for some fusion types. RNA-Seq assay detected 10 of 12 gene fusions detected by DNA based NGS assay, for a sensitivity of 83%. No false-positive gene fusions were identified in 28 tumor specimens that were negative for fusions, for a specificity of 100%. The assay also identified 6 novel fusions in 3 tumor specimens, which had been confirmed by RT-PCR and Sanger sequencing. Good intra-assay and inter assay reproducibility was observed with complete concordance for the presence or absence of gene fusions in 3 samples and 6 replicates. We observed 81% success rate on whole transcriptome RNA-Seq process for more than 100 FFPE samples.
Conclusions
RNA-Seq assay can help identify gene fusions in patients with cancer, which is a good supplement for DNA based NGS assay, especially for novel fusion detection or fusion breakpoints which are hard to design probes for DNA samples. These patients may in turn benefit from approved and investigational fusion related targeted therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
3DMed Inc.
Funding
3DMed Inc.
Disclosure
H. Dong: Full / Part-time employment: 3DMed Inc. C. Wang: Full / Part-time employment: 3DMed Inc. Q. Xu: Full / Part-time employment: 3DMed Inc. Y. Guo: Full / Part-time employment: 3DMed Inc. Y. Chen: Full / Part-time employment: 3DMed Inc. B. Li: Full / Part-time employment: 3DMed Inc. S. Liu: Full / Part-time employment: 3DMed Inc. C. Chen: Full / Part-time employment: 3DMed Inc. L. Xiong: Full / Part-time employment: 3DMed Inc. F. Li: Full / Part-time employment: 3DMed Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract